nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNA3—skin epidermis—melanoma	0.0334	0.167	CbGeAlD
Varenicline—CHRNA7—skin epidermis—melanoma	0.0218	0.109	CbGeAlD
Varenicline—CHRNA6—skin of body—melanoma	0.0186	0.0929	CbGeAlD
Varenicline—CHRNA6—head—melanoma	0.0121	0.0606	CbGeAlD
Varenicline—CHRNA3—eye—melanoma	0.0119	0.0595	CbGeAlD
Varenicline—CHRNA3—retina—melanoma	0.0118	0.059	CbGeAlD
Varenicline—CHRNA7—neck—melanoma	0.0105	0.0522	CbGeAlD
Varenicline—CHRNA3—skin of body—melanoma	0.0104	0.0518	CbGeAlD
Varenicline—CHRNB2—mammalian vulva—melanoma	0.00974	0.0487	CbGeAlD
Varenicline—CHRNA7—eye—melanoma	0.00778	0.0389	CbGeAlD
Varenicline—CHRNA7—retina—melanoma	0.00771	0.0385	CbGeAlD
Varenicline—CHRNB2—head—melanoma	0.00697	0.0348	CbGeAlD
Varenicline—CHRNA7—skin of body—melanoma	0.00677	0.0338	CbGeAlD
Varenicline—CHRNA3—head—melanoma	0.00676	0.0338	CbGeAlD
Varenicline—CHRFAM7A—head—melanoma	0.00547	0.0273	CbGeAlD
Varenicline—CHRNB2—lymph node—melanoma	0.00488	0.0244	CbGeAlD
Varenicline—CHRNA3—lymph node—melanoma	0.00473	0.0237	CbGeAlD
Varenicline—CHRNA7—head—melanoma	0.00442	0.0221	CbGeAlD
Varenicline—CHRNA4—head—melanoma	0.00436	0.0218	CbGeAlD
Varenicline—Lethargy—Docetaxel—melanoma	0.00162	0.00212	CcSEcCtD
Varenicline—Urethral disorder—Temozolomide—melanoma	0.00162	0.00212	CcSEcCtD
Varenicline—Eye disorder—Carmustine—melanoma	0.0016	0.00209	CcSEcCtD
Varenicline—Visual impairment—Temozolomide—melanoma	0.00159	0.00208	CcSEcCtD
Varenicline—Erythema—Dactinomycin—melanoma	0.00159	0.00208	CcSEcCtD
Varenicline—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.00159	0.00208	CcSEcCtD
Varenicline—Ill-defined disorder—Bleomycin—melanoma	0.00158	0.00207	CcSEcCtD
Varenicline—Anaemia—Bleomycin—melanoma	0.00158	0.00206	CcSEcCtD
Varenicline—Diarrhoea—Vemurafenib—melanoma	0.00157	0.00206	CcSEcCtD
Varenicline—Migraine—Docetaxel—melanoma	0.00156	0.00205	CcSEcCtD
Varenicline—Erythema multiforme—Temozolomide—melanoma	0.00156	0.00204	CcSEcCtD
Varenicline—Eye disorder—Temozolomide—melanoma	0.00154	0.00202	CcSEcCtD
Varenicline—Tinnitus—Temozolomide—melanoma	0.00154	0.00202	CcSEcCtD
Varenicline—Malaise—Bleomycin—melanoma	0.00154	0.00201	CcSEcCtD
Varenicline—Cardiac disorder—Temozolomide—melanoma	0.00153	0.00201	CcSEcCtD
Varenicline—Arrhythmia—Carmustine—melanoma	0.00153	0.002	CcSEcCtD
Varenicline—Dizziness—Vemurafenib—melanoma	0.00152	0.00199	CcSEcCtD
Varenicline—Angiopathy—Temozolomide—melanoma	0.0015	0.00196	CcSEcCtD
Varenicline—Mental disorder—Carmustine—melanoma	0.0015	0.00196	CcSEcCtD
Varenicline—Immune system disorder—Temozolomide—melanoma	0.00149	0.00195	CcSEcCtD
Varenicline—Mediastinal disorder—Temozolomide—melanoma	0.00149	0.00195	CcSEcCtD
Varenicline—Malnutrition—Carmustine—melanoma	0.00149	0.00195	CcSEcCtD
Varenicline—Erythema—Carmustine—melanoma	0.00149	0.00195	CcSEcCtD
Varenicline—Cough—Bleomycin—melanoma	0.00149	0.00195	CcSEcCtD
Varenicline—Chills—Temozolomide—melanoma	0.00148	0.00194	CcSEcCtD
Varenicline—Ill-defined disorder—Dactinomycin—melanoma	0.00148	0.00193	CcSEcCtD
Varenicline—Anaemia—Dactinomycin—melanoma	0.00147	0.00192	CcSEcCtD
Varenicline—Liver function test abnormal—Docetaxel—melanoma	0.00147	0.00192	CcSEcCtD
Varenicline—Vomiting—Vemurafenib—melanoma	0.00146	0.00191	CcSEcCtD
Varenicline—Dry skin—Docetaxel—melanoma	0.00146	0.0019	CcSEcCtD
Varenicline—Myalgia—Bleomycin—melanoma	0.00145	0.0019	CcSEcCtD
Varenicline—Chest pain—Bleomycin—melanoma	0.00145	0.0019	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—POU3F2—melanoma	0.00145	0.0412	CbGpPWpGaD
Varenicline—Abdominal pain upper—Docetaxel—melanoma	0.00145	0.0019	CcSEcCtD
Varenicline—Rash—Vemurafenib—melanoma	0.00145	0.00189	CcSEcCtD
Varenicline—Mental disorder—Temozolomide—melanoma	0.00145	0.00189	CcSEcCtD
Varenicline—Dermatitis—Vemurafenib—melanoma	0.00145	0.00189	CcSEcCtD
Varenicline—Back pain—Carmustine—melanoma	0.00144	0.00188	CcSEcCtD
Varenicline—Headache—Vemurafenib—melanoma	0.00144	0.00188	CcSEcCtD
Varenicline—Erythema—Temozolomide—melanoma	0.00144	0.00188	CcSEcCtD
Varenicline—Malnutrition—Temozolomide—melanoma	0.00144	0.00188	CcSEcCtD
Varenicline—Breast disorder—Docetaxel—melanoma	0.00144	0.00188	CcSEcCtD
Varenicline—Discomfort—Bleomycin—melanoma	0.00143	0.00188	CcSEcCtD
Varenicline—Malaise—Dactinomycin—melanoma	0.00143	0.00188	CcSEcCtD
Varenicline—Cramp muscle—Docetaxel—melanoma	0.00143	0.00187	CcSEcCtD
Varenicline—Nasopharyngitis—Docetaxel—melanoma	0.00142	0.00186	CcSEcCtD
Varenicline—Dysgeusia—Temozolomide—melanoma	0.00141	0.00184	CcSEcCtD
Varenicline—Vision blurred—Carmustine—melanoma	0.0014	0.00183	CcSEcCtD
Varenicline—Tremor—Carmustine—melanoma	0.00139	0.00182	CcSEcCtD
Varenicline—Oedema—Bleomycin—melanoma	0.00139	0.00182	CcSEcCtD
Varenicline—Back pain—Temozolomide—melanoma	0.00139	0.00182	CcSEcCtD
Varenicline—Infection—Bleomycin—melanoma	0.00138	0.00181	CcSEcCtD
Varenicline—Anaemia—Carmustine—melanoma	0.00138	0.0018	CcSEcCtD
Varenicline—Dysphagia—Docetaxel—melanoma	0.00137	0.0018	CcSEcCtD
Varenicline—Agitation—Carmustine—melanoma	0.00137	0.00179	CcSEcCtD
Varenicline—Nausea—Vemurafenib—melanoma	0.00136	0.00178	CcSEcCtD
Varenicline—Thrombocytopenia—Bleomycin—melanoma	0.00136	0.00178	CcSEcCtD
Varenicline—Vision blurred—Temozolomide—melanoma	0.00136	0.00177	CcSEcCtD
Varenicline—Myalgia—Dactinomycin—melanoma	0.00135	0.00177	CcSEcCtD
Varenicline—Tremor—Temozolomide—melanoma	0.00135	0.00176	CcSEcCtD
Varenicline—Discomfort—Dactinomycin—melanoma	0.00134	0.00175	CcSEcCtD
Varenicline—Angina pectoris—Docetaxel—melanoma	0.00134	0.00175	CcSEcCtD
Varenicline—Ill-defined disorder—Temozolomide—melanoma	0.00133	0.00175	CcSEcCtD
Varenicline—Anaemia—Temozolomide—melanoma	0.00133	0.00174	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—RAI1—melanoma	0.00133	0.0378	CbGpPWpGaD
Varenicline—Anorexia—Bleomycin—melanoma	0.00133	0.00174	CcSEcCtD
Varenicline—Agitation—Temozolomide—melanoma	0.00132	0.00173	CcSEcCtD
Varenicline—Angioedema—Temozolomide—melanoma	0.00131	0.00172	CcSEcCtD
Varenicline—Hypotension—Bleomycin—melanoma	0.0013	0.0017	CcSEcCtD
Varenicline—Oedema—Dactinomycin—melanoma	0.0013	0.0017	CcSEcCtD
Varenicline—Malaise—Temozolomide—melanoma	0.0013	0.0017	CcSEcCtD
Varenicline—Vertigo—Temozolomide—melanoma	0.00129	0.00169	CcSEcCtD
Varenicline—Convulsion—Carmustine—melanoma	0.00129	0.00169	CcSEcCtD
Varenicline—Infection—Dactinomycin—melanoma	0.00129	0.00169	CcSEcCtD
Varenicline—Hypertension—Carmustine—melanoma	0.00129	0.00168	CcSEcCtD
Varenicline—Palpitations—Temozolomide—melanoma	0.00127	0.00166	CcSEcCtD
Varenicline—Thrombocytopenia—Dactinomycin—melanoma	0.00127	0.00166	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Bleomycin—melanoma	0.00127	0.00166	CcSEcCtD
Varenicline—Myalgia—Carmustine—melanoma	0.00127	0.00166	CcSEcCtD
Varenicline—Chest pain—Carmustine—melanoma	0.00127	0.00166	CcSEcCtD
Varenicline—Anxiety—Carmustine—melanoma	0.00126	0.00165	CcSEcCtD
Varenicline—Cough—Temozolomide—melanoma	0.00126	0.00164	CcSEcCtD
Varenicline—Weight increased—Docetaxel—melanoma	0.00125	0.00163	CcSEcCtD
Varenicline—Convulsion—Temozolomide—melanoma	0.00125	0.00163	CcSEcCtD
Varenicline—Hypertension—Temozolomide—melanoma	0.00124	0.00162	CcSEcCtD
Varenicline—Dyspnoea—Bleomycin—melanoma	0.00124	0.00162	CcSEcCtD
Varenicline—Anorexia—Dactinomycin—melanoma	0.00124	0.00162	CcSEcCtD
Varenicline—Arthralgia—Temozolomide—melanoma	0.00122	0.0016	CcSEcCtD
Varenicline—Myalgia—Temozolomide—melanoma	0.00122	0.0016	CcSEcCtD
Varenicline—Infestation NOS—Docetaxel—melanoma	0.00122	0.0016	CcSEcCtD
Varenicline—Infestation—Docetaxel—melanoma	0.00122	0.0016	CcSEcCtD
Varenicline—Anxiety—Temozolomide—melanoma	0.00122	0.0016	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00122	0.00159	CcSEcCtD
Varenicline—Oedema—Carmustine—melanoma	0.00122	0.00159	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00121	0.00159	CcSEcCtD
Varenicline—Discomfort—Temozolomide—melanoma	0.00121	0.00158	CcSEcCtD
Varenicline—Decreased appetite—Bleomycin—melanoma	0.00121	0.00158	CcSEcCtD
Varenicline—Infection—Carmustine—melanoma	0.00121	0.00158	CcSEcCtD
Varenicline—Acute coronary syndrome—Docetaxel—melanoma	0.00121	0.00158	CcSEcCtD
Varenicline—Myocardial infarction—Docetaxel—melanoma	0.0012	0.00157	CcSEcCtD
Varenicline—Dry mouth—Temozolomide—melanoma	0.0012	0.00157	CcSEcCtD
Varenicline—Stomatitis—Docetaxel—melanoma	0.00119	0.00156	CcSEcCtD
Varenicline—Pain—Bleomycin—melanoma	0.00119	0.00156	CcSEcCtD
Varenicline—Conjunctivitis—Docetaxel—melanoma	0.00119	0.00156	CcSEcCtD
Varenicline—Thrombocytopenia—Carmustine—melanoma	0.00119	0.00156	CcSEcCtD
Varenicline—Tachycardia—Carmustine—melanoma	0.00119	0.00155	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00118	0.00155	CcSEcCtD
Varenicline—Oedema—Temozolomide—melanoma	0.00117	0.00154	CcSEcCtD
Varenicline—Infection—Temozolomide—melanoma	0.00117	0.00153	CcSEcCtD
Varenicline—Anorexia—Carmustine—melanoma	0.00116	0.00151	CcSEcCtD
Varenicline—Hepatobiliary disease—Docetaxel—melanoma	0.00116	0.00151	CcSEcCtD
Varenicline—Epistaxis—Docetaxel—melanoma	0.00115	0.00151	CcSEcCtD
Varenicline—Nervous system disorder—Temozolomide—melanoma	0.00115	0.00151	CcSEcCtD
Varenicline—Thrombocytopenia—Temozolomide—melanoma	0.00115	0.0015	CcSEcCtD
Varenicline—Feeling abnormal—Bleomycin—melanoma	0.00115	0.0015	CcSEcCtD
Varenicline—Skin disorder—Temozolomide—melanoma	0.00114	0.00149	CcSEcCtD
Varenicline—Hypotension—Carmustine—melanoma	0.00114	0.00148	CcSEcCtD
Varenicline—Hyperhidrosis—Temozolomide—melanoma	0.00114	0.00148	CcSEcCtD
Varenicline—Decreased appetite—Dactinomycin—melanoma	0.00113	0.00148	CcSEcCtD
Varenicline—Fatigue—Dactinomycin—melanoma	0.00112	0.00146	CcSEcCtD
Varenicline—Anorexia—Temozolomide—melanoma	0.00112	0.00146	CcSEcCtD
Varenicline—Pain—Dactinomycin—melanoma	0.00111	0.00145	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Carmustine—melanoma	0.00111	0.00145	CcSEcCtD
Varenicline—Urticaria—Bleomycin—melanoma	0.00111	0.00145	CcSEcCtD
Varenicline—Body temperature increased—Bleomycin—melanoma	0.0011	0.00144	CcSEcCtD
Varenicline—Insomnia—Carmustine—melanoma	0.0011	0.00144	CcSEcCtD
Varenicline—Hypoaesthesia—Docetaxel—melanoma	0.00109	0.00143	CcSEcCtD
Varenicline—Urinary tract disorder—Docetaxel—melanoma	0.00109	0.00142	CcSEcCtD
Varenicline—Dyspnoea—Carmustine—melanoma	0.00108	0.00142	CcSEcCtD
Varenicline—Oedema peripheral—Docetaxel—melanoma	0.00108	0.00142	CcSEcCtD
Varenicline—Somnolence—Carmustine—melanoma	0.00108	0.00141	CcSEcCtD
Varenicline—Connective tissue disorder—Docetaxel—melanoma	0.00108	0.00141	CcSEcCtD
Varenicline—Urethral disorder—Docetaxel—melanoma	0.00108	0.00141	CcSEcCtD
Varenicline—Feeling abnormal—Dactinomycin—melanoma	0.00107	0.0014	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Temozolomide—melanoma	0.00107	0.0014	CcSEcCtD
Varenicline—Insomnia—Temozolomide—melanoma	0.00106	0.00139	CcSEcCtD
Varenicline—Gastrointestinal pain—Dactinomycin—melanoma	0.00106	0.00139	CcSEcCtD
Varenicline—Visual impairment—Docetaxel—melanoma	0.00106	0.00139	CcSEcCtD
Varenicline—Decreased appetite—Carmustine—melanoma	0.00106	0.00138	CcSEcCtD
Varenicline—Gastrointestinal disorder—Carmustine—melanoma	0.00105	0.00137	CcSEcCtD
Varenicline—Dyspnoea—Temozolomide—melanoma	0.00105	0.00137	CcSEcCtD
Varenicline—Somnolence—Temozolomide—melanoma	0.00104	0.00137	CcSEcCtD
Varenicline—Erythema multiforme—Docetaxel—melanoma	0.00104	0.00136	CcSEcCtD
Varenicline—Pain—Carmustine—melanoma	0.00104	0.00136	CcSEcCtD
Varenicline—Constipation—Carmustine—melanoma	0.00104	0.00136	CcSEcCtD
Varenicline—Dyspepsia—Temozolomide—melanoma	0.00103	0.00135	CcSEcCtD
Varenicline—Eye disorder—Docetaxel—melanoma	0.00103	0.00134	CcSEcCtD
Varenicline—Body temperature increased—Dactinomycin—melanoma	0.00103	0.00134	CcSEcCtD
Varenicline—Abdominal pain—Dactinomycin—melanoma	0.00103	0.00134	CcSEcCtD
Varenicline—Hypersensitivity—Bleomycin—melanoma	0.00103	0.00134	CcSEcCtD
Varenicline—Decreased appetite—Temozolomide—melanoma	0.00102	0.00133	CcSEcCtD
Varenicline—Cardiac disorder—Docetaxel—melanoma	0.00102	0.00133	CcSEcCtD
Varenicline—Gastrointestinal disorder—Temozolomide—melanoma	0.00101	0.00133	CcSEcCtD
Varenicline—Fatigue—Temozolomide—melanoma	0.00101	0.00132	CcSEcCtD
Varenicline—Pain—Temozolomide—melanoma	0.001	0.00131	CcSEcCtD
Varenicline—Constipation—Temozolomide—melanoma	0.001	0.00131	CcSEcCtD
Varenicline—Feeling abnormal—Carmustine—melanoma	0.001	0.00131	CcSEcCtD
Varenicline—Asthenia—Bleomycin—melanoma	0.000999	0.00131	CcSEcCtD
Varenicline—Angiopathy—Docetaxel—melanoma	0.000997	0.0013	CcSEcCtD
Varenicline—Gastrointestinal pain—Carmustine—melanoma	0.000994	0.0013	CcSEcCtD
Varenicline—Immune system disorder—Docetaxel—melanoma	0.000993	0.0013	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—POU3F2—melanoma	0.000992	0.0282	CbGpPWpGaD
Varenicline—Mediastinal disorder—Docetaxel—melanoma	0.000991	0.0013	CcSEcCtD
Varenicline—Chills—Docetaxel—melanoma	0.000986	0.00129	CcSEcCtD
Varenicline—Pruritus—Bleomycin—melanoma	0.000985	0.00129	CcSEcCtD
Varenicline—Arrhythmia—Docetaxel—melanoma	0.000982	0.00128	CcSEcCtD
Varenicline—Feeling abnormal—Temozolomide—melanoma	0.000968	0.00127	CcSEcCtD
Varenicline—Mental disorder—Docetaxel—melanoma	0.000963	0.00126	CcSEcCtD
Varenicline—Body temperature increased—Carmustine—melanoma	0.000961	0.00126	CcSEcCtD
Varenicline—Abdominal pain—Carmustine—melanoma	0.000961	0.00126	CcSEcCtD
Varenicline—Gastrointestinal pain—Temozolomide—melanoma	0.00096	0.00126	CcSEcCtD
Varenicline—Erythema—Docetaxel—melanoma	0.000957	0.00125	CcSEcCtD
Varenicline—Malnutrition—Docetaxel—melanoma	0.000957	0.00125	CcSEcCtD
Varenicline—Hypersensitivity—Dactinomycin—melanoma	0.000956	0.00125	CcSEcCtD
Varenicline—Dysgeusia—Docetaxel—melanoma	0.000937	0.00123	CcSEcCtD
Varenicline—Urticaria—Temozolomide—melanoma	0.000933	0.00122	CcSEcCtD
Varenicline—Asthenia—Dactinomycin—melanoma	0.000931	0.00122	CcSEcCtD
Varenicline—Abdominal pain—Temozolomide—melanoma	0.000928	0.00121	CcSEcCtD
Varenicline—Body temperature increased—Temozolomide—melanoma	0.000928	0.00121	CcSEcCtD
Varenicline—Back pain—Docetaxel—melanoma	0.000925	0.00121	CcSEcCtD
Varenicline—Muscle spasms—Docetaxel—melanoma	0.00092	0.0012	CcSEcCtD
Varenicline—Hypersensitivity—Carmustine—melanoma	0.000895	0.00117	CcSEcCtD
Varenicline—Diarrhoea—Dactinomycin—melanoma	0.000888	0.00116	CcSEcCtD
Varenicline—Vomiting—Bleomycin—melanoma	0.000885	0.00116	CcSEcCtD
Varenicline—Anaemia—Docetaxel—melanoma	0.000884	0.00116	CcSEcCtD
Varenicline—Rash—Bleomycin—melanoma	0.000878	0.00115	CcSEcCtD
Varenicline—Dermatitis—Bleomycin—melanoma	0.000877	0.00115	CcSEcCtD
Varenicline—Asthenia—Carmustine—melanoma	0.000872	0.00114	CcSEcCtD
Varenicline—Hypersensitivity—Temozolomide—melanoma	0.000865	0.00113	CcSEcCtD
Varenicline—Syncope—Docetaxel—melanoma	0.000858	0.00112	CcSEcCtD
Varenicline—Palpitations—Docetaxel—melanoma	0.000846	0.00111	CcSEcCtD
Varenicline—Asthenia—Temozolomide—melanoma	0.000842	0.0011	CcSEcCtD
Varenicline—Loss of consciousness—Docetaxel—melanoma	0.000841	0.0011	CcSEcCtD
Varenicline—Cough—Docetaxel—melanoma	0.000835	0.00109	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—MAP2—melanoma	0.000834	0.0237	CbGpPWpGaD
Varenicline—Diarrhoea—Carmustine—melanoma	0.000831	0.00109	CcSEcCtD
Varenicline—Pruritus—Temozolomide—melanoma	0.000831	0.00109	CcSEcCtD
Varenicline—Convulsion—Docetaxel—melanoma	0.000829	0.00108	CcSEcCtD
Varenicline—Nausea—Bleomycin—melanoma	0.000827	0.00108	CcSEcCtD
Varenicline—Hypertension—Docetaxel—melanoma	0.000826	0.00108	CcSEcCtD
Varenicline—Vomiting—Dactinomycin—melanoma	0.000825	0.00108	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—SLC6A11—melanoma	0.000819	0.0233	CbGpPWpGaD
Varenicline—Rash—Dactinomycin—melanoma	0.000819	0.00107	CcSEcCtD
Varenicline—Arthralgia—Docetaxel—melanoma	0.000815	0.00107	CcSEcCtD
Varenicline—Myalgia—Docetaxel—melanoma	0.000815	0.00107	CcSEcCtD
Varenicline—Chest pain—Docetaxel—melanoma	0.000815	0.00107	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000809	0.00106	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—POU3F2—melanoma	0.000809	0.023	CbGpPWpGaD
Varenicline—Dizziness—Carmustine—melanoma	0.000803	0.00105	CcSEcCtD
Varenicline—Diarrhoea—Temozolomide—melanoma	0.000803	0.00105	CcSEcCtD
Varenicline—Dry mouth—Docetaxel—melanoma	0.000797	0.00104	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—ARNT—melanoma	0.000791	0.0225	CbGpPWpGaD
Varenicline—Oedema—Docetaxel—melanoma	0.000781	0.00102	CcSEcCtD
Varenicline—Dizziness—Temozolomide—melanoma	0.000776	0.00102	CcSEcCtD
Varenicline—Infection—Docetaxel—melanoma	0.000776	0.00101	CcSEcCtD
Varenicline—Vomiting—Carmustine—melanoma	0.000773	0.00101	CcSEcCtD
Varenicline—Nausea—Dactinomycin—melanoma	0.000771	0.00101	CcSEcCtD
Varenicline—Shock—Docetaxel—melanoma	0.000768	0.001	CcSEcCtD
Varenicline—Rash—Carmustine—melanoma	0.000766	0.001	CcSEcCtD
Varenicline—Nervous system disorder—Docetaxel—melanoma	0.000766	0.001	CcSEcCtD
Varenicline—Dermatitis—Carmustine—melanoma	0.000765	0.001	CcSEcCtD
Varenicline—Thrombocytopenia—Docetaxel—melanoma	0.000765	0.001	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—PAX4—melanoma	0.000764	0.0217	CbGpPWpGaD
Varenicline—Tachycardia—Docetaxel—melanoma	0.000762	0.000997	CcSEcCtD
Varenicline—Headache—Carmustine—melanoma	0.000761	0.000995	CcSEcCtD
Varenicline—Skin disorder—Docetaxel—melanoma	0.000758	0.000992	CcSEcCtD
Varenicline—Vomiting—Temozolomide—melanoma	0.000747	0.000976	CcSEcCtD
Varenicline—Anorexia—Docetaxel—melanoma	0.000744	0.000973	CcSEcCtD
Varenicline—Rash—Temozolomide—melanoma	0.00074	0.000968	CcSEcCtD
Varenicline—Dermatitis—Temozolomide—melanoma	0.00074	0.000967	CcSEcCtD
Varenicline—Headache—Temozolomide—melanoma	0.000736	0.000962	CcSEcCtD
Varenicline—Hypotension—Docetaxel—melanoma	0.00073	0.000954	CcSEcCtD
Varenicline—Nausea—Carmustine—melanoma	0.000722	0.000944	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—SLC6A11—melanoma	0.000721	0.0205	CbGpPWpGaD
Varenicline—Musculoskeletal discomfort—Docetaxel—melanoma	0.000711	0.00093	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TP73—melanoma	0.000709	0.0201	CbGpPWpGaD
Varenicline—Insomnia—Docetaxel—melanoma	0.000706	0.000924	CcSEcCtD
Varenicline—Nausea—Temozolomide—melanoma	0.000697	0.000912	CcSEcCtD
Varenicline—Dyspnoea—Docetaxel—melanoma	0.000696	0.00091	CcSEcCtD
Varenicline—Somnolence—Docetaxel—melanoma	0.000694	0.000908	CcSEcCtD
Varenicline—Dyspepsia—Docetaxel—melanoma	0.000687	0.000899	CcSEcCtD
Varenicline—Decreased appetite—Docetaxel—melanoma	0.000679	0.000888	CcSEcCtD
Varenicline—Gastrointestinal disorder—Docetaxel—melanoma	0.000674	0.000882	CcSEcCtD
Varenicline—Fatigue—Docetaxel—melanoma	0.000673	0.00088	CcSEcCtD
Varenicline—Pain—Docetaxel—melanoma	0.000668	0.000873	CcSEcCtD
Varenicline—Constipation—Docetaxel—melanoma	0.000668	0.000873	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIN2A—melanoma	0.000665	0.0189	CbGpPWpGaD
Varenicline—Feeling abnormal—Docetaxel—melanoma	0.000643	0.000842	CcSEcCtD
Varenicline—Gastrointestinal pain—Docetaxel—melanoma	0.000639	0.000835	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—SLC6A11—melanoma	0.000627	0.0178	CbGpPWpGaD
Varenicline—Body temperature increased—Docetaxel—melanoma	0.000617	0.000807	CcSEcCtD
Varenicline—Abdominal pain—Docetaxel—melanoma	0.000617	0.000807	CcSEcCtD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIN2A—melanoma	0.000586	0.0166	CbGpPWpGaD
Varenicline—Hypersensitivity—Docetaxel—melanoma	0.000575	0.000752	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—MAP2—melanoma	0.00057	0.0162	CbGpPWpGaD
Varenicline—Asthenia—Docetaxel—melanoma	0.00056	0.000733	CcSEcCtD
Varenicline—Pruritus—Docetaxel—melanoma	0.000552	0.000722	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—SLC6A11—melanoma	0.000552	0.0157	CbGpPWpGaD
Varenicline—Diarrhoea—Docetaxel—melanoma	0.000534	0.000699	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—SLC6A11—melanoma	0.000519	0.0147	CbGpPWpGaD
Varenicline—Dizziness—Docetaxel—melanoma	0.000516	0.000675	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—GRIN2A—melanoma	0.0005	0.0142	CbGpPWpGaD
Varenicline—Vomiting—Docetaxel—melanoma	0.000496	0.000649	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—SLC6A11—melanoma	0.000493	0.014	CbGpPWpGaD
Varenicline—Rash—Docetaxel—melanoma	0.000492	0.000644	CcSEcCtD
Varenicline—Dermatitis—Docetaxel—melanoma	0.000492	0.000643	CcSEcCtD
Varenicline—Headache—Docetaxel—melanoma	0.000489	0.00064	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TP73—melanoma	0.000484	0.0138	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—MAP2—melanoma	0.000464	0.0132	CbGpPWpGaD
Varenicline—Nausea—Docetaxel—melanoma	0.000464	0.000607	CcSEcCtD
Varenicline—CHRNB2—Transmission across Chemical Synapses—GRIN2A—melanoma	0.00044	0.0125	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIN2A—melanoma	0.000422	0.012	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—SLC6A11—melanoma	0.000402	0.0114	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIN2A—melanoma	0.0004	0.0114	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—SLC6A11—melanoma	0.000398	0.0113	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TP73—melanoma	0.000395	0.0112	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—GRIN2A—melanoma	0.000383	0.0109	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—SLC6A11—melanoma	0.000377	0.0107	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCA—melanoma	0.00035	0.00993	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—GNA11—melanoma	0.000341	0.00969	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—GRIN2A—melanoma	0.000337	0.00958	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIN2A—melanoma	0.000326	0.00927	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—HDAC2—melanoma	0.000321	0.00911	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—GNAQ—melanoma	0.000317	0.00901	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—GRIN2A—melanoma	0.000317	0.00901	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCA—melanoma	0.000308	0.00874	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—SLC6A11—melanoma	0.000308	0.00874	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—GRIN2A—melanoma	0.000301	0.00855	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL10—melanoma	0.000298	0.00846	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NGFR—melanoma	0.000293	0.00831	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—PRKCA—melanoma	0.000263	0.00746	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—melanoma	0.000257	0.00731	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HIF1A—melanoma	0.000251	0.00713	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—GRIN2A—melanoma	0.000245	0.00697	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—GRIN2A—melanoma	0.000243	0.0069	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—PRKCA—melanoma	0.000231	0.00657	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—GRIN2A—melanoma	0.000231	0.00655	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—melanoma	0.000227	0.00644	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCA—melanoma	0.000222	0.00629	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—FAS—melanoma	0.000218	0.00619	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—melanoma	0.000216	0.00612	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCA—melanoma	0.00021	0.00597	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL10—melanoma	0.000203	0.00578	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—PRKCA—melanoma	0.000201	0.00572	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—BRAF—melanoma	0.000193	0.00549	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—CDK4—melanoma	0.000192	0.00545	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—melanoma	0.00019	0.00539	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—GRIN2A—melanoma	0.000188	0.00534	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NOS2—melanoma	0.000186	0.00529	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—PRKCA—melanoma	0.000177	0.00503	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PPARG—melanoma	0.000174	0.00495	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HIF1A—melanoma	0.000171	0.00487	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKCA—melanoma	0.000171	0.00487	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—BRAF—melanoma	0.00017	0.00484	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—PRKCA—melanoma	0.000167	0.00473	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL10—melanoma	0.000166	0.00471	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—melanoma	0.000163	0.00463	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CXCL8—melanoma	0.000163	0.00462	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MDM2—melanoma	0.000162	0.0046	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—PRKCA—melanoma	0.000158	0.00449	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—melanoma	0.000156	0.00442	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—melanoma	0.000155	0.0044	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.00015	0.00427	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—BRAF—melanoma	0.000148	0.00421	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—melanoma	0.000147	0.00419	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—NFKB1—melanoma	0.000146	0.00414	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MDM2—melanoma	0.000143	0.00405	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HIF1A—melanoma	0.00014	0.00397	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—melanoma	0.000137	0.00388	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—melanoma	0.000132	0.00375	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—BRAF—melanoma	0.00013	0.00371	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—melanoma	0.00013	0.00369	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—melanoma	0.00013	0.00368	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—PRKCA—melanoma	0.000129	0.00366	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—PRKCA—melanoma	0.000128	0.00363	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—melanoma	0.000126	0.00358	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—MDM2—melanoma	0.000124	0.00353	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—BRAF—melanoma	0.000123	0.00348	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—PRKCA—melanoma	0.000121	0.00344	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—PTEN—melanoma	0.000119	0.00339	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—melanoma	0.000118	0.00336	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—BRAF—melanoma	0.000116	0.00331	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TNF—melanoma	0.000113	0.00322	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CXCL8—melanoma	0.000111	0.00316	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MAPK1—melanoma	0.000111	0.00315	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—MDM2—melanoma	0.000109	0.00311	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—melanoma	0.000106	0.00302	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—melanoma	0.000106	0.003	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—melanoma	0.000104	0.00296	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MDM2—melanoma	0.000103	0.00292	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.000103	0.00291	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—NFKB1—melanoma	9.95e-05	0.00283	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—PRKCA—melanoma	9.87e-05	0.0028	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MAPK1—melanoma	9.75e-05	0.00277	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MDM2—melanoma	9.75e-05	0.00277	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—BRAF—melanoma	9.49e-05	0.00269	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—BRAF—melanoma	9.4e-05	0.00267	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—melanoma	9.34e-05	0.00265	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6—melanoma	9.14e-05	0.0026	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CXCL8—melanoma	9.07e-05	0.00258	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—melanoma	9.03e-05	0.00257	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—BRAF—melanoma	8.92e-05	0.00253	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—HRAS—melanoma	8.89e-05	0.00253	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—melanoma	8.87e-05	0.00252	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—melanoma	8.68e-05	0.00246	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—MAPK1—melanoma	8.49e-05	0.00241	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CTNNB1—melanoma	8.36e-05	0.00238	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—melanoma	8.16e-05	0.00232	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—NFKB1—melanoma	8.11e-05	0.0023	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MDM2—melanoma	7.95e-05	0.00226	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—MDM2—melanoma	7.87e-05	0.00224	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—HRAS—melanoma	7.83e-05	0.00222	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TNF—melanoma	7.74e-05	0.0022	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—melanoma	7.5e-05	0.00213	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—MAPK1—melanoma	7.47e-05	0.00212	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—MDM2—melanoma	7.47e-05	0.00212	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—IL6—melanoma	7.46e-05	0.00212	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—melanoma	7.36e-05	0.00209	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—BRAF—melanoma	7.27e-05	0.00206	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—melanoma	7.23e-05	0.00205	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—melanoma	7.12e-05	0.00202	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MAPK1—melanoma	7.02e-05	0.00199	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—HRAS—melanoma	6.81e-05	0.00194	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MAPK1—melanoma	6.66e-05	0.00189	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TNF—melanoma	6.31e-05	0.00179	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6—melanoma	6.25e-05	0.00177	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—MDM2—melanoma	6.09e-05	0.00173	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—HRAS—melanoma	6e-05	0.0017	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—melanoma	5.8e-05	0.00165	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—HRAS—melanoma	5.64e-05	0.0016	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MAPK1—melanoma	5.43e-05	0.00154	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—MAPK1—melanoma	5.38e-05	0.00153	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—HRAS—melanoma	5.35e-05	0.00152	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—MAPK1—melanoma	5.11e-05	0.00145	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6—melanoma	5.09e-05	0.00145	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—HRAS—melanoma	4.36e-05	0.00124	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—HRAS—melanoma	4.32e-05	0.00123	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—MAPK1—melanoma	4.16e-05	0.00118	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—HRAS—melanoma	4.1e-05	0.00116	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—HRAS—melanoma	3.34e-05	0.000949	CbGpPWpGaD
